Afyx Therapeutics A/S — Credit Rating and Financial Key Figures
CVR number: 38793594
Slotsmarken 11, 2970 Hørsholm
cm@inphena.com
tel: 71747174
www.afyxtx.com
Income statement (kDKK)
2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Fiscal period length | 12 | 12 | 12 | 12 | 12 |
| Net sales | |||||
| Gross profit | - 585.93 | 1 509.14 | -3 345.74 | 11 236.77 | 23 467.83 |
| Employee benefit expenses | - 720.98 | -1 971.80 | -2 302.02 | -4 174.10 | -13 709.30 |
| Other operating expenses | -10 147.51 | -9 985.62 | |||
| Total depreciation | - 317.85 | - 561.89 | -1 010.20 | -6.93 | |
| EBIT | -1 624.76 | -1 024.55 | -6 657.95 | -3 084.84 | - 234.02 |
| Other financial income | 7.36 | 141.78 | |||
| Other financial expenses | -65.29 | - 144.95 | -61.23 | - 215.23 | -29.12 |
| Reduction non-current investment assets | -23.39 | ||||
| Net income from associates (fin.) | -75.00 | -1 454.44 | |||
| Pre-tax profit | -1 690.05 | -1 185.52 | -6 719.19 | -3 375.06 | -1 575.81 |
| Income taxes | 183.40 | 371.34 | -1 150.37 | 2 392.72 | -2 234.77 |
| Net earnings | -1 506.65 | - 814.18 | -7 869.56 | - 982.34 | -3 810.59 |
Assets (kDKK)
2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Development expenditure | 3 613.17 | 4 739.21 | 5 502.84 | ||
| Intangible assets total | 3 613.17 | 4 739.21 | 5 502.84 | ||
| Machinery and equipment | 568.84 | ||||
| Tangible assets total | 568.84 | ||||
| Holdings in group member companies | 23.39 | 19.80 | 19.80 | ||
| Investments total | 23.39 | 101.92 | 326.50 | 866.79 | |
| Long term receivables total | |||||
| Finished products/goods | 786.63 | 1 467.73 | |||
| Inventories total | 786.63 | 1 467.73 | |||
| Current trade debtors | 878.68 | 1 162.99 | 421.70 | 3 139.95 | 4 094.83 |
| Current amounts owed by group member comp. | 1 054.49 | 2 379.53 | 0.00 | 6 328.04 | |
| Prepayments and accrued income | 17.77 | 205.86 | 535.53 | ||
| Current other receivables | 302.06 | 640.87 | 346.94 | 514.57 | 67.80 |
| Current deferred tax assets | 2 418.17 | ||||
| Short term receivables total | 2 235.23 | 4 183.40 | 786.40 | 6 278.55 | 11 026.20 |
| Cash and bank deposits | 223.21 | 853.63 | 5 665.34 | 2 899.09 | 1 533.28 |
| Cash and cash equivalents | 223.21 | 853.63 | 5 665.34 | 2 899.09 | 1 533.28 |
| Balance sheet total (assets) | 6 095.00 | 9 776.24 | 12 056.50 | 10 290.77 | 15 462.84 |
Equity and liabilities (kDKK)
2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Share capital | 1 205.70 | 3 566.70 | 3 566.70 | 4 566.70 | 18 831.75 |
| Share premium account | 7 000.00 | 7 000.00 | |||
| Other reserves | 2 818.27 | 3 696.58 | 4 292.21 | ||
| Retained earnings | 2 178.70 | - 206.26 | -1 020.44 | -11 378.71 | -12 361.06 |
| Profit of the financial year | -1 506.65 | - 814.18 | -7 869.56 | - 982.34 | -3 810.59 |
| Shareholders equity total | 4 696.03 | 6 242.85 | -1 031.08 | - 794.35 | 9 660.11 |
| Provisions | 4 104.56 | ||||
| Non-current liabilities total | |||||
| Current trade creditors | 30.00 | 60.00 | 1 838.05 | 4 940.65 | 3 384.32 |
| Current owed to group member | 1 058.94 | 2 394.48 | 11 094.16 | 1 479.61 | 17.26 |
| Other non-interest bearing current liabilities | 310.03 | 1 078.92 | 155.38 | 560.31 | 2 401.16 |
| Current liabilities total | 1 398.97 | 3 533.39 | 13 087.59 | 6 980.56 | 5 802.73 |
| Balance sheet total (liabilities) | 6 095.00 | 9 776.24 | 12 056.50 | 10 290.77 | 15 462.84 |
Try the full version of our system for free
- Professional credit risk reports
- Create your own estimates for any company
- Valuation analysis
- All 400,000+ Danish companies
- See instructions
... and more!
No registration needed.